Literature DB >> 15073143

Precocious puberty and statural growth.

Jean-Claude Carel1, Najiba Lahlou, Marc Roger, Jean Louis Chaussain.   

Abstract

Precocious puberty results mostly from the precocious activation of the gonadotropic axis. Although the age limits have recently been discussed, most physicians consider that onset of pubertal development before the age of 8 years in a girl or 9 years in a boy warrants at least a clinical and bone age evaluation by a paediatric endocrinologist. The major concern in precocious puberty is the underlying condition, and central nervous system or gonadal neoplasm have to be formally excluded as a first step in the diagnosis. A secondary concern is height, since precocious puberty leads to accelerated growth, accelerated bone maturation and ultimately reduced stature. Precocious puberty is heterogeneous and strict criteria should be used to define it, both in terms of age and in terms of potential for progression. Depot forms of GnRH agonists are now the standard treatment for progressive central precocious puberty and aim at alleviating the clinical symptoms of early pubertal development, their psychological consequences and the effects on growth. Here, we review the consequences of both central and gonadotropin-independent precocious puberty on adult stature and the information available on outcomes using the therapeutic regimens currently available. In girls with progressive precocious puberty, all published evidence indicates a gain of adult height over height predicted before treatment or over untreated historical controls. However, the apparent height gain (derived from the comparison of predicted and actual heights) is very variable, in large part due to the inaccuracy of height prediction methods. In girls with onset of puberty at the lower half of the normal age (8-10 years) distribution, trials using GnRH agonists have given negative results (no benefit of treatment). In boys, precocious puberty is rare and fewer results are available but point in the same direction. The most appropriate time for interrupting the treatment is still controversial. In conclusion, GnRH agonists restore adult height in children when it is compromised by precocious puberty.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15073143     DOI: 10.1093/humupd/dmh012

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  63 in total

1.  Male reproductive health after childhood, adolescent, and young adult cancers: a report from the Children's Oncology Group.

Authors:  Lisa B Kenney; Laurie E Cohen; Margarett Shnorhavorian; Monika L Metzger; Barbara Lockart; Nobuko Hijiya; Eileen Duffey-Lind; Louis Constine; Daniel Green; Lillian Meacham
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

Review 2.  Genomic and non-genomic actions of sex steroids in the growth plate.

Authors:  Marcel Karperien; Bram C J van der Eerden; Jan Maarten Wit
Journal:  Pediatr Nephrol       Date:  2005-02-03       Impact factor: 3.714

3.  Forensic age assessment of asylum seekers in Finland.

Authors:  Mari Metsäniitty; Olli Varkkola; Janna Waltimo-Sirén; Helena Ranta
Journal:  Int J Legal Med       Date:  2016-11-25       Impact factor: 2.686

4.  Body size in early life and breast cancer risk in African American and European American women.

Authors:  Elisa V Bandera; Urmila Chandran; Gary Zirpoli; Gregory Ciupak; Dana H Bovbjerg; Lina Jandorf; Karen Pawlish; Jo L Freudenheim; Christine B Ambrosone
Journal:  Cancer Causes Control       Date:  2013-10-10       Impact factor: 2.506

5.  Evidence that estrogen hastens epiphyseal fusion and cessation of longitudinal bone growth by irreversibly depleting the number of resting zone progenitor cells in female rabbits.

Authors:  Ola Nilsson; Martina Weise; Ellie B M Landman; Jodi L Meyers; Kevin M Barnes; Jeffrey Baron
Journal:  Endocrinology       Date:  2014-04-07       Impact factor: 4.736

Review 6.  Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications.

Authors:  Monika L Metzger; Lillian R Meacham; Briana Patterson; Jacqueline S Casillas; Louis S Constine; Nobuko Hijiya; Lisa B Kenney; Marcia Leonard; Barbara A Lockart; Wendy Likes; Daniel M Green
Journal:  J Clin Oncol       Date:  2013-02-04       Impact factor: 44.544

7.  Consumption of soy-based infant formula is not associated with early onset of puberty.

Authors:  Tali Sinai; Shely Ben-Avraham; Inbal Guelmann-Mizrahi; Michael R Goldberg; Larisa Naugolni; Galia Askapa; Yitzhak Katz; Marianna Rachmiel
Journal:  Eur J Nutr       Date:  2018-03-20       Impact factor: 5.614

8.  Central Precocious Puberty: Update on Diagnosis and Treatment.

Authors:  Melinda Chen; Erica A Eugster
Journal:  Paediatr Drugs       Date:  2015-08       Impact factor: 3.022

Review 9.  Sexual precocity and its treatment.

Authors:  DeAnna B Brown; Lindsey A Loomba-Albrecht; Andrew A Bremer
Journal:  World J Pediatr       Date:  2013-05-16       Impact factor: 2.764

10.  Development of a bioassay system for human growth hormone determination with close correlation to immunoassay.

Authors:  M Maimaiti; Y Tanahashi; Z Mohri; K Fujieda
Journal:  J Clin Lab Anal       Date:  2012-09       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.